Clin2
NCT07744529Possibly a fitRecruiting

Combination treatment for lung cancer spread to the lining of the brain

Leptomeningeal Metastasis From Lung Cancer

Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.

This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
15 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have a lung cancer type called EGFR-mutated lung adenocarcinoma.
  • The cancer has spread to the lining of the brain and spinal cord (leptomeningeal metastasis).
  • You are at least 18 years old.
  • You are expected to live at least 3 more months.
  • Your major organs (kidneys, liver, heart, and bone marrow) are working well enough.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07751536Recruiting
Proton radiation and intrathecal chemo for lung cancer that has spread to the brain lining

This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.

Hefei, Anhui
NCT06663306Recruiting· Phase 1
Intrathecal pemetrexed and bevacizumab for lung cancer brain spread

This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.

Shanghai
NCT06901817Recruiting· Phase 2
Study of pemetrexed plus nivolumab for lung cancer that has spread to the lining of the brain

This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.

Shanghai, Shanghai Municipality
NCT07398599Recruiting
Double-dose targeted therapy plus chemo for lung cancer spread to brain lining

This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.

Nanchang, Jiangxi
NCT06441045Not yet recruiting· Phase 2
Double-dose targeted therapy with or without spinal fluid chemotherapy for lung cancer that has spread to the brain lining

This study tests whether giving a higher dose of an EGFR-targeted pill, either alone or with a chemotherapy drug injected into the fluid around the spinal cord, can control lung cancer that has spread to the lining of the brain (called leptomeningeal metastases). It is for people whose cancer has gotten worse in the brain lining while on a standard dose of this type of medication.

Fuzhou, Fujian
NCT06296745Recruiting· Phase 2
Pemetrexed in spinal fluid for lung cancer that spread to brain lining

This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.

Huizhou, Guangdong

Hear when a new Leptomeningeal Metastasis From Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.